Results 121 to 130 of about 691,224 (357)
Interventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...
Bingchen Guo +7 more
wiley +1 more source
F(ab')2 fragments of anti-Mo1 (904) monoclonal antibodies do not prevent myocardial stunning. [PDF]
, 1989 Robert J. Schott +6 more
openalex +1 more source
A Case of Myocardial Stunning in Hyperthyroidism
Korean Circulation Journal, 2004 Although myocardial stunning occurs in coronary artery disease, it has rarely been reported with hyperthyroidism. A 72-year-old woman presented with general weakness, shortness of breath and febrile sensation of 10 days duration. The serum thyroid hormone level was elevated.
Si Hoon Park +3 more
openaire +2 more sources
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
K-ATP channel gene expression is induced by urocortin and mediates its cardioprotective effect [PDF]
, 2002 Background-Urocortin is a novel cardioprotective agent that can protect cardiac myocytes from the damaging effects of ischemia/reperfusion both in culture and in the intact heart and is effective when given at reperfusion.Methods and Results-We have ...
Chanalaris, A +11 more
core
Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy [PDF]
, 2018 Background: Recent hypotheses have suggested the pathophysiological role of catecholamines in the evolution of the Takotsubo syndrome (TTS). The extent of cardiac and circulatory compromise dictates the use of some form of supportive therapy.
Akin, Ibrahim +9 more
core +1 more source
Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
ESC Heart Failure, Volume 12, Issue 2, Page 1304-1315, April 2025.Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén +16 more
wiley +1 more source
A paradigm shift in myocardial stunning
Journal of the American College of Cardiology, 2002 The study by Burnes et al. [(1)][1]in a recent issue of JACC was presented to show the close correlation of reconstructed and measured electrograms in and out of ventricular tachycardia, in a chronic (four-day-old) infarction model.
openaire +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García +17 more
wiley +1 more source